<DOC>
	<DOC>NCT03079999</DOC>
	<brief_summary>This is a phase II prospective, randomized, double-blind, longitudinal study evaluating whether the administration of aspirin can delay or slow tumor growth and maintain or improve hearing in VS patients.</brief_summary>
	<brief_title>Study of Aspirin in Patients With Vestibular Schwannoma</brief_title>
	<detailed_description />
	<mesh_term>Neurofibromatoses</mesh_term>
	<mesh_term>Neurofibroma</mesh_term>
	<mesh_term>Neurilemmoma</mesh_term>
	<mesh_term>Neuroma</mesh_term>
	<mesh_term>Neuroma, Acoustic</mesh_term>
	<mesh_term>Neurofibromatosis 2</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>Radiographic diagnosis of vestibular schwannoma (NF2associated or sporadic). Ageâ‰¥12 years. Ability to provide informed consent.Pediatric patients must provide assent in addition to their parents'/guardians' consent. Adult patients who cannot consent for themselves will not be eligible to participate in this study. Ability to swallow tablets. Inability to perform volumetric measurements of vestibular schwannoma(s). Inability to tolerate MRI with contrast. Daily use of aspirin within the last two months. Occasional use of aspirin for pain relief is not exclusionary. Known allergy to aspirin. Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of aspirin. Pregnant or lactating women. Patients with serious medical illnesses (e.g. severe asthma) that in the option of the investigator could prevent participation in the trial. Active bleeding diathesis. Hydrocephalus from brainstem compression. Febrile illness or flulike illness in children and adolescents less than 18 years of age.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>